Pfizer and biontech submit covid-19 vaccine stability data at standard freezer temperature to the u.s. fda

New york and mainz, germany, february 19, 2021 (globe newswire) — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced the submission of new data to the u.s. food and drug administration (fda) demonstrating the stability of their covid-19 vaccine when stored at -25°c to -15°c (-13°f to 5°f), temperatures more commonly found in pharmaceutical freezers and refrigerators. the data have been submitted to the fda to support a proposed update to the u.s. emergency use authorization (eua) prescribing information, which would allow for vaccine vials to be stored at these temperatures for a total of two weeks as an alternative or complement to storage in an ultra-low temperature freezer.
BNTX Ratings Summary
BNTX Quant Ranking